{
    "clinical_study": {
        "@rank": "154701", 
        "acronym": "VBY036P1B", 
        "arm_group": [
            {
                "arm_group_label": "VBY-036", 
                "arm_group_type": "Experimental", 
                "description": "VBY-036 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg"
            }, 
            {
                "arm_group_label": "Placebo comparator", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "VBY-036 may treat or prevent nerve pain.  This study aims to find the highest safe and\n      tolerable dose of VBY-036 in healthy volunteers. Volunteers will be randomly selected to\n      receive either a placebo or VBY-036 (30, 100, 300, 600 or 900 mg) once daily for seven days\n      in a row."
        }, 
        "brief_title": "Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Detailed description is noted in Brief Summary."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, 18-60 years old\n\n          -  Screening body mass index between 18-32 kg/m2\n\n          -  Good health, no clinically significant findings in medical history, 12-lead ECG, &\n             vital signs;\n\n          -  Clinical lab evaluations (Chem panel [fasted at least 8 hrs], CBC, HbA1c & UA in\n             reference range for test lab (unless deemed not clinically significant);\n\n          -  Negative test for drugs of abuse at Screening & at Check-in (includes alcohol);\n\n          -  Negative hepatitis, HIV & TB screens;\n\n          -  Females non-pregnant, non-lactating, & either postmenopausal for at least 1 year,\n             surgically sterile for at least 90 days prior to Check-in, or agree to use from the\n             time of consent until 90 days after Study Completion an effective form of\n             contraception.   For all females, a pregnancy test result must be negative at\n             Screening & Check-in.\n\n          -  Males will be sterile or agree to use from Check-in until 90 days following discharge\n             an effective method of contraception.\n\n          -  Able to comprehend & willing to sign Informed Consent Form\n\n        Exclusion Criteria:\n\n          -  Females pregnant or nursing, or childbearing potential but unwilling to use\n             contraception.\n\n          -  History of renal or hepatic impairment; stomach or intestinal surgery or resection,\n             malabsorption syndrome, cholecystectomy, or gastro-intestinal dysfunction that would\n             alter absorption &/or excretion of orally administered drugs (appendectomy or hernia\n             repair allowed);\n\n          -  Anemia (hemoglobin <11.5 g/dL for females; < 13 g/dL for males) or blood donation\n             within 8 weeks of Check-in;\n\n          -  Plasma donation within 4 weeks of Check-in;\n\n          -  History of alcoholism or drug addiction within 6 months to Check-in;\n\n          -  Use of drugs of abuse or prescription drugs for recreational use 6 months prior to\n             Check-in;\n\n          -  Use of any tobacco-containing or nicotine-containing products 6 months prior to\n             Check-in & during study;\n\n          -  Participation in another drug trial 30 days of Check-in (within 8 weeks if previous\n             investigational drug has immunomodulary effects, other than cathepsin S inhibition);\n\n          -  History or clinical manifestations of metabolic, hepatic, renal, hematological,\n             pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric\n             disorders\n\n          -  History of hypersensitivity or allergies to any drug compound\n\n          -  History or presence of abnormal ECG\n\n          -  Laboratory abnormality deemed clinically significant;\n\n          -  Use of or inability to discontinue any prescription medications/products 14 days\n             prior to Check-in & during study;\n\n          -  Use of certain over-the-counter, non-prescription preparations are permitted up to 3\n             days before first dose;\n\n          -  Use of alcohol-containing, grapefruit-containing, star fruit containing foods or\n             beverages or \"energy drinks\" 72 hours to Check-in & during study;\n\n          -  Poor peripheral venous access;\n\n          -  Receipt of blood products 6 months to Check-in\n\n          -  Subjects with history of Gilbert's Syndrome;\n\n          -  Strenuous activities 48 hours to Check-in\n\n          -  Illness 5 days to drug administration\n\n          -  Any acute or chronic condition"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892891", 
            "org_study_id": "VBY-036-002"
        }, 
        "intervention": {
            "arm_group_label": "VBY-036", 
            "description": "Cathepsin S inhibitor", 
            "intervention_name": "VBY-036", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy", 
            "Subjects", 
            "Safety", 
            "Tolerability", 
            "VBY036", 
            "maximum", 
            "pharmacodynamic", 
            "pharmacokinetic"
        ], 
        "lastchanged_date": "December 27, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Evansville", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "47710"
                }, 
                "name": "Covance Evansville"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled, Sequential, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-036 in Healthy Subjects", 
        "other_outcome": {
            "description": "The blood level of VBY-036 across the dose range of 30 mg to 900 mg", 
            "measure": "The blood level of VBY-036", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "overall_official": {
            "affiliation": "Virobay Inc.", 
            "last_name": "David B. Karpf, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Single dose of VBY-036 given daily for 7-days in a row for each cohort in an ascending manner.\nCohort B1 with 30 mg dose or placebo; Cohort B2 with 100 mg dose or placebo; Cohort B3 with 300 mg dose or placebo; Cohort B4 with 600 mg dose or placebo; Cohort B5 with 900 mg dose or placebo", 
            "measure": "Highest safe and tolerated VBY-036 dose", 
            "safety_issue": "Yes", 
            "time_frame": "7 days of dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892891"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Based on the accumulation of Iip 10 and/or cathepsin S protein levels", 
            "measure": "Confirmation of cathepsin-S inhibition", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "source": "Virobay Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Virobay Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}